Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy

Yang Li; Jianfeng Gao; Shuping Wang; Shijun Li; Xiaowen Hou; Yanna Pan; Jialu Gao; Xue Qiao; Zhiquan Tian; Deliang Chen; Hai Deng; Zixin Deng; Xuechuan Hong; Yuling Xiao

doi:10.1016/j.jconrel.2022.01.005

Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy

Yang Li, Jianfeng Gao, Shuping Wang, Shijun Li, Xiaowen Hou, Yanna Pan, Jialu Gao, Xue Qiao, Zhiquan Tian, Deliang Chen, Hai Deng, Zixin Deng, Xuechuan Hong, Yuling Xiao^*

^*Corresponding author for this work

Chemistry

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

6 Downloads (Pure)

Abstract

Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.

Original language	English
Pages (from-to)	157-169
Number of pages	13
Journal	Journal of Controlled Release
Volume	342
Early online date	5 Jan 2022
DOIs	https://doi.org/10.1016/j.jconrel.2022.01.005
Publication status	Published - 1 Feb 2022

Bibliographical note

Acknowledgments
This work was partially supported by grants from the National Key R&D Program of China (2020YFA0908800), NSFC (82111530209, 81773674, 91959103, 81573383, 21763002), Shenzhen Science and Technology Research Grant (JCYJ20190808152019182), the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (2019020701011429), Hubei Province Scientific and Technical Innovation Key Project (2020BAB058), the Local Development Funds of Science and Technology Department of Tibet (XZ202102YD0033C, XZ202001YD0028C), and the Fundamental Research Funds for the Central Universities.

Keywords

China
Drug delivery
Image-guided therapy
Second near-infrared window (NIR-II)
Self-assembly
Fluorescence imaging

Access to Document

10.1016/j.jconrel.2022.01.005Licence: CC BY-NC-ND

Li_et_al_Organic_NIR_II_Journal_of_Controlled_Release_vor
© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license https://creativecommons.org/licenses/by-nc-nd/4.0/
Final published version, 16 MBLicence: CC BY-NC-ND

Cite this

@article{0a1e6ff524b54a9e82f8cb4c617b619f,

title = "Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy",

abstract = "Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.",

keywords = "China, Drug delivery, Image-guided therapy, Second near-infrared window (NIR-II), Self-assembly, Fluorescence imaging",

author = "Yang Li and Jianfeng Gao and Shuping Wang and Shijun Li and Xiaowen Hou and Yanna Pan and Jialu Gao and Xue Qiao and Zhiquan Tian and Deliang Chen and Hai Deng and Zixin Deng and Xuechuan Hong and Yuling Xiao",

note = "Acknowledgments This work was partially supported by grants from the National Key R&D Program of China (2020YFA0908800), NSFC (82111530209, 81773674, 91959103, 81573383, 21763002), Shenzhen Science and Technology Research Grant (JCYJ20190808152019182), the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (2019020701011429), Hubei Province Scientific and Technical Innovation Key Project (2020BAB058), the Local Development Funds of Science and Technology Department of Tibet (XZ202102YD0033C, XZ202001YD0028C), and the Fundamental Research Funds for the Central Universities.",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/j.jconrel.2022.01.005",

language = "English",

volume = "342",

pages = "157--169",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier",

}

TY - JOUR

T1 - Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy

AU - Li, Yang

AU - Gao, Jianfeng

AU - Wang, Shuping

AU - Li, Shijun

AU - Hou, Xiaowen

AU - Pan, Yanna

AU - Gao, Jialu

AU - Qiao, Xue

AU - Tian, Zhiquan

AU - Chen, Deliang

AU - Deng, Hai

AU - Deng, Zixin

AU - Hong, Xuechuan

AU - Xiao, Yuling

N1 - Acknowledgments This work was partially supported by grants from the National Key R&D Program of China (2020YFA0908800), NSFC (82111530209, 81773674, 91959103, 81573383, 21763002), Shenzhen Science and Technology Research Grant (JCYJ20190808152019182), the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (2019020701011429), Hubei Province Scientific and Technical Innovation Key Project (2020BAB058), the Local Development Funds of Science and Technology Department of Tibet (XZ202102YD0033C, XZ202001YD0028C), and the Fundamental Research Funds for the Central Universities.

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.

AB - Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.

KW - China

KW - Drug delivery

KW - Image-guided therapy

KW - Second near-infrared window (NIR-II)

KW - Self-assembly

KW - Fluorescence imaging

U2 - 10.1016/j.jconrel.2022.01.005

DO - 10.1016/j.jconrel.2022.01.005

M3 - Article

SN - 0168-3659

VL - 342

SP - 157

EP - 169

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this